UY38376A - Inhibidores de o-glicoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa - Google Patents
Inhibidores de o-glicoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasaInfo
- Publication number
- UY38376A UY38376A UY0001038376A UY38376A UY38376A UY 38376 A UY38376 A UY 38376A UY 0001038376 A UY0001038376 A UY 0001038376A UY 38376 A UY38376 A UY 38376A UY 38376 A UY38376 A UY 38376A
- Authority
- UY
- Uruguay
- Prior art keywords
- glucopyranosidase
- acetamido
- deoxy
- glycoprotein
- inhibitors
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
Abstract
En la presente se describen compuestos representados por las fórmulas (IA) o (IB) o una sal farmacéuticamente aceptable de estos, composiciones farmacéuticas que los comprenden y métodos para prepararlos y utilizarlos. Las variables R1, R3, R4, Y1, Y2, Ar, Z y n son como se definen en la presente.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862733484P | 2018-09-19 | 2018-09-19 | |
| US201862750000P | 2018-10-24 | 2018-10-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY38376A true UY38376A (es) | 2020-04-30 |
Family
ID=68073263
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001038376A UY38376A (es) | 2018-09-19 | 2019-09-18 | Inhibidores de o-glicoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US12180205B2 (es) |
| EP (1) | EP3853226A1 (es) |
| JP (2) | JP7606960B2 (es) |
| KR (1) | KR20210060513A (es) |
| CN (2) | CN119219621A (es) |
| AU (1) | AU2019344922B2 (es) |
| BR (1) | BR112021004739A2 (es) |
| CA (1) | CA3113009A1 (es) |
| CL (1) | CL2021000646A1 (es) |
| CO (1) | CO2021004873A2 (es) |
| CR (1) | CR20210181A (es) |
| IL (2) | IL315564A (es) |
| JO (1) | JOP20210036A1 (es) |
| MA (1) | MA53648A (es) |
| MX (1) | MX2021003232A (es) |
| PE (1) | PE20211591A1 (es) |
| PH (1) | PH12021550439A1 (es) |
| SG (1) | SG11202102379XA (es) |
| UY (1) | UY38376A (es) |
| WO (1) | WO2020061150A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230061395A (ko) * | 2020-08-03 | 2023-05-08 | 바이오젠 엠에이 인코포레이티드 | O-당단백질-2-아세트아미도-2-데옥시-3-d-글루코피라노시다제 억제제의 결정질 형태 |
| KR102533471B1 (ko) * | 2020-11-23 | 2023-05-19 | (주) 메디프론디비티 | O-GlcNAcase 저해 활성을 갖는 화합물 및 이의 용도 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
| EP1351936A1 (en) | 2001-01-15 | 2003-10-15 | Glaxo Group Limited | Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression |
| US7829712B2 (en) | 2004-09-20 | 2010-11-09 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives for inhibiting human stearoyl-CoA-desaturase |
| RU2505540C2 (ru) | 2008-12-23 | 2014-01-27 | Эббви Инк. | Антивирусные соединения |
| WO2011143495A1 (en) | 2010-05-13 | 2011-11-17 | Amgen Inc. | Heteroaryloxyheterocyclyl compounds as pde10 inhibitors |
| US9206128B2 (en) | 2011-11-18 | 2015-12-08 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| WO2013075084A1 (en) | 2011-11-18 | 2013-05-23 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
| WO2013078320A1 (en) | 2011-11-21 | 2013-05-30 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
| EP2812001B1 (en) | 2012-02-10 | 2017-06-14 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| WO2013170072A2 (en) | 2012-05-09 | 2013-11-14 | Neurop, Inc. | Compounds for the treatment of neurological disorders |
| KR20150079711A (ko) | 2012-10-31 | 2015-07-08 | 알렉토스 테라퓨틱스 인크. | 글리코시다아제 저해제 및 이의 용도 |
| ME02730B (me) | 2013-02-11 | 2017-10-20 | Constellation Pharmaceuticals Inc | Modulatori enzima koji modifikuju metil, njihove kompozicije i upotreba |
| CA2899088C (en) | 2013-03-14 | 2022-12-20 | Merck Patent Gmbh | Thiazole and oxazole compounds as glycosidase inhibitors |
| EP2970305B1 (en) | 2013-03-15 | 2017-02-22 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| EP3033334A1 (en) | 2013-08-15 | 2016-06-22 | Constellation Pharmaceuticals, Inc. | Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof |
| DK3092236T3 (en) | 2014-01-06 | 2020-11-30 | Rhizen Pharmaceuticals S A | Nye glutaminaseinhibitorer |
| WO2016107603A1 (zh) | 2015-01-01 | 2016-07-07 | 成都贝斯凯瑞生物科技有限公司 | 取代氮杂环衍生物及其应用 |
| CN110300752A (zh) * | 2016-12-16 | 2019-10-01 | 詹森药业有限公司 | 单环oga抑制剂化合物 |
| CN110312716A (zh) | 2016-12-16 | 2019-10-08 | 詹森药业有限公司 | 双环oga抑制剂化合物 |
| TWI654978B (zh) * | 2017-01-27 | 2019-04-01 | 美商美國禮來大藥廠 | 5－甲基－1,2,4－二唑－3－基化合物 |
| MX2020009530A (es) | 2018-03-14 | 2021-01-15 | Biogen Ma Inc | Inhibidores de la o-glicoproteína-2-acetamido-2-desoxi-3-dglicopir anosidasa. |
| US11459324B2 (en) | 2018-03-14 | 2022-10-04 | Biogen Ma Inc. | O-glycoprotein-2-acetamido-2-deoxy-3-D-glycopyranosidase inhibitors |
| US20210300900A1 (en) | 2018-06-20 | 2021-09-30 | Janssen Pharmaceutica Nv | Oga inhibitor compounds |
-
2019
- 2019-09-18 AU AU2019344922A patent/AU2019344922B2/en active Active
- 2019-09-18 MA MA053648A patent/MA53648A/fr unknown
- 2019-09-18 JP JP2021515045A patent/JP7606960B2/ja active Active
- 2019-09-18 WO PCT/US2019/051661 patent/WO2020061150A1/en active Application Filing
- 2019-09-18 CN CN202411009108.7A patent/CN119219621A/zh active Pending
- 2019-09-18 PE PE2021000333A patent/PE20211591A1/es unknown
- 2019-09-18 SG SG11202102379XA patent/SG11202102379XA/en unknown
- 2019-09-18 JO JOP/2021/0036A patent/JOP20210036A1/ar unknown
- 2019-09-18 CN CN201980060829.1A patent/CN113166137B/zh active Active
- 2019-09-18 MX MX2021003232A patent/MX2021003232A/es unknown
- 2019-09-18 BR BR112021004739-5A patent/BR112021004739A2/pt unknown
- 2019-09-18 EP EP19779339.1A patent/EP3853226A1/en active Pending
- 2019-09-18 UY UY0001038376A patent/UY38376A/es unknown
- 2019-09-18 IL IL315564A patent/IL315564A/en unknown
- 2019-09-18 IL IL281514A patent/IL281514B2/en unknown
- 2019-09-18 CR CR20210181A patent/CR20210181A/es unknown
- 2019-09-18 CA CA3113009A patent/CA3113009A1/en active Pending
- 2019-09-18 US US17/276,502 patent/US12180205B2/en active Active
- 2019-09-18 KR KR1020217010451A patent/KR20210060513A/ko not_active Application Discontinuation
-
2021
- 2021-03-02 PH PH12021550439A patent/PH12021550439A1/en unknown
- 2021-03-16 CL CL2021000646A patent/CL2021000646A1/es unknown
- 2021-04-16 CO CONC2021/0004873A patent/CO2021004873A2/es unknown
-
2024
- 2024-05-24 US US18/673,619 patent/US20240308995A1/en active Pending
- 2024-09-27 JP JP2024168726A patent/JP2025011144A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL281514B1 (en) | 2024-10-01 |
| WO2020061150A1 (en) | 2020-03-26 |
| SG11202102379XA (en) | 2021-04-29 |
| KR20210060513A (ko) | 2021-05-26 |
| US12180205B2 (en) | 2024-12-31 |
| EP3853226A1 (en) | 2021-07-28 |
| MA53648A (fr) | 2021-07-28 |
| CR20210181A (es) | 2021-07-01 |
| IL281514B2 (en) | 2025-02-01 |
| JP2022500472A (ja) | 2022-01-04 |
| JP7606960B2 (ja) | 2024-12-26 |
| IL315564A (en) | 2024-11-01 |
| JP2025011144A (ja) | 2025-01-23 |
| CA3113009A1 (en) | 2020-03-26 |
| BR112021004739A2 (pt) | 2021-06-01 |
| PH12021550439A1 (en) | 2021-11-29 |
| PE20211591A1 (es) | 2021-08-18 |
| US20240308995A1 (en) | 2024-09-19 |
| CN113166137B (zh) | 2024-08-16 |
| CN119219621A (zh) | 2024-12-31 |
| AU2019344922B2 (en) | 2025-02-06 |
| US20220041586A1 (en) | 2022-02-10 |
| MX2021003232A (es) | 2021-07-16 |
| TW202031651A (zh) | 2020-09-01 |
| CL2021000646A1 (es) | 2021-09-03 |
| JOP20210036A1 (ar) | 2021-02-25 |
| CO2021004873A2 (es) | 2021-07-30 |
| AU2019344922A1 (en) | 2021-03-25 |
| CN113166137A (zh) | 2021-07-23 |
| IL281514A (en) | 2021-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2018000270A (es) | Nuevos derivados piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
| CO2018000589A2 (es) | Oxiesteroles y composiciones farmacéuticas que los contienen | |
| NI201800133A (es) | Nuevos derivados piperidinilo sustituidos con (hetero) arilo, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
| CL2017003258A1 (es) | Nuevos derivados hidroxiéster, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
| UY35362A (es) | Compuestos terapéuticos | |
| MX2020009530A (es) | Inhibidores de la o-glicoproteína-2-acetamido-2-desoxi-3-dglicopir anosidasa. | |
| CU20180073A7 (es) | Nuevos derivados de amonio, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
| NI201200132A (es) | Derivados de arilmetoxi isoindolina y composiciones que los comprenden y metodos para utilizar los mismos | |
| CL2017000820A1 (es) | Compuestos de aminopurina sustituida, composiciones de los mismos, y metodos de tratamiento con los mismos | |
| UY35818A (es) | Composiciones y métodos para modular los receptores x farnesoides | |
| UY36651A (es) | Compuestos antiestrogénicos | |
| CL2017002354A1 (es) | Compuestos derivados de heteroarilos bicíclicos fusionados con actividad como inhibidores de phd. | |
| ECSP22038509A (es) | Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1 | |
| CL2018001067A1 (es) | Compuesto piranodipiridínico. | |
| CO2021004873A2 (es) | Inhibidores de o-glicoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa | |
| CO2017009989A2 (es) | Piridopirimidinonas y utilización de las mismas como moduladores de receptores de nmda | |
| CL2021000973A1 (es) | Nuevos derivados amino-pirimidonil-piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen. | |
| EA202090978A1 (ru) | Новые макроциклические производные, способ их получения и содержащие их фармацевтические композиции | |
| CU20220025A7 (es) | Inihibidores del factor d del complemento para administración oral | |
| UY38567A (es) | Inhibidores de o-glucoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa de éter bicíclico | |
| UY38498A (es) | Inhibidores de o-glucoproteina-2- acetamido-2-desoxi-3-d-glucopiranosidasa de morfolinilo , piperazinilo , oxazepanilo y diazepanilo | |
| UY38934A (es) | Inhibidores de o-glucoproteína-2-acetamido-2-deoxi-3-d-glucopiranosidasa espirocíclica | |
| ECSP18056196A (es) | Derivados de indano | |
| CO2022006942A2 (es) | Compuestos de 1,8-naftiridin-2-ona para el tratamiento de una enfermedad autoinmunitaria | |
| EA202190707A1 (ru) | Ингибиторы о-гликопротеин-2-ацетамидо-2-деокси-3-d-глюкопиранозидазы |